Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT00125827 Completed - Solid Tumors Clinical Trials

Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This is a research study of clofarabine that will be given to patients (orally) with advanced cancerous tumors or cancerous tumors that have spread in which standard drugs are no longer effective or no reliable effective treatment is available. The purpose of this study is to find the answers to the following research questions: 1. What is the largest dose of oral clofarabine that can be safely given daily for 5 days followed by 23 days of rest and repeated every 28 days? 2. What are the side effects of clofarabine when given on this schedule? 3. How much oral clofarabine is in the blood at specific times after administration and how does the body get rid of the drug? 4. Will oral clofarabine help treat solid tumor cancer?

NCT ID: NCT00091806 Completed - Solid Tumors Clinical Trials

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.

NCT ID: NCT00033215 Completed - Solid Tumors Clinical Trials

A Phase 1 Study of S-3304 in Patients With Solid Tumors

Start date: November 2001
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population